EFFICACY AND SAFETY OF ANTI-TNFα HUMAN MONOCLONAL ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND SECONDARY RESISTANCE TO OTHER GENETICALLY ENGINEERED BIOLOGICAL AGENTS
Treatment of juvenile idiopathic arthritis (JIA) is one of the most important challenges in paediatric rheumatology. The results of the retrospective observational study of adalimumab (anti TNF human monoclonal antibodies) efficacy and safety in real clinical practice in treatment of 56 patients wit...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2012-07-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/458 |
| _version_ | 1797697560139268096 |
|---|---|
| author | E. I. Alexeeva T. M. Bzarova S. I. Valieva R. V. Denisova K. B. Isaeva A. M. Chomakhidze E. G. Chistyakova T. V. Sleptsova E. V. Mitenko N. I. Taibulatov |
| author_facet | E. I. Alexeeva T. M. Bzarova S. I. Valieva R. V. Denisova K. B. Isaeva A. M. Chomakhidze E. G. Chistyakova T. V. Sleptsova E. V. Mitenko N. I. Taibulatov |
| author_sort | E. I. Alexeeva |
| collection | DOAJ |
| description | Treatment of juvenile idiopathic arthritis (JIA) is one of the most important challenges in paediatric rheumatology. The results of the retrospective observational study of adalimumab (anti TNF human monoclonal antibodies) efficacy and safety in real clinical practice in treatment of 56 patients with JIA and primary or secondary resistance to other genetically engineered biological agents (48 — infiximab, 2 — etanercept, 5 — rituximab, 1 — abatacept) are demonstrated in this article. Adalimumab was administered hypodermically at the dosage of 40 mg per 2 weeks. The efficacy was assessed according to the criteria of ACR (pediatric). In 4 weeks of treatment in 100% of patients the 30% improvement was established, in 80% of patients — 50% improvement, and in 60% of patients — 70% improvement. In 25 weeks of treatment 30% improvement was documented in 100% of patients (56), 50% improvement — in 91% (51), 70% improvement — in 74% (41). Inactive stage of the disease was established in 24 weeks in 55% of children; in 1 year — in 85%; remission was established in 55% of children. No severe side effects were found. Therefore, the received data show that adalimumab is effective in patients with JIA, both with primary and secondary resistance to other biological agents. |
| first_indexed | 2024-03-12T03:41:56Z |
| format | Article |
| id | doaj.art-b999bc8684ed4ebfab0234e2d8eb683f |
| institution | Directory Open Access Journal |
| issn | 1682-5527 1682-5535 |
| language | English |
| last_indexed | 2024-03-12T03:41:56Z |
| publishDate | 2012-07-01 |
| publisher | "Paediatrician" Publishers LLC |
| record_format | Article |
| series | Вопросы современной педиатрии |
| spelling | doaj.art-b999bc8684ed4ebfab0234e2d8eb683f2023-09-03T13:02:31Zeng"Paediatrician" Publishers LLCВопросы современной педиатрии1682-55271682-55352012-07-01114828810.15690/vsp.v11i4.363458EFFICACY AND SAFETY OF ANTI-TNFα HUMAN MONOCLONAL ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND SECONDARY RESISTANCE TO OTHER GENETICALLY ENGINEERED BIOLOGICAL AGENTSE. I. Alexeeva0T. M. Bzarova1S. I. Valieva2R. V. Denisova3K. B. Isaeva4A. M. Chomakhidze5E. G. Chistyakova6T. V. Sleptsova7E. V. Mitenko8N. I. Taibulatov9Научный центр здоровья детей РАМН, Москва; Первый Московский государственный медицинский университет им. И.М. Сеченова, МоскваНаучный центр здоровья детей РАМН, МоскваНаучный центр здоровья детей РАМН, МоскваНаучный центр здоровья детей РАМН, МоскваНаучный центр здоровья детей РАМН, МоскваНаучный центр здоровья детей РАМН, МоскваНаучный центр здоровья детей РАМН, Москва; Первый Московский государственный медицинский университет им. И.М. Сеченова, МоскваНаучный центр здоровья детей РАМН, МоскваНаучный центр здоровья детей РАМН, МоскваНаучный центр здоровья детей РАМН, МоскваTreatment of juvenile idiopathic arthritis (JIA) is one of the most important challenges in paediatric rheumatology. The results of the retrospective observational study of adalimumab (anti TNF human monoclonal antibodies) efficacy and safety in real clinical practice in treatment of 56 patients with JIA and primary or secondary resistance to other genetically engineered biological agents (48 — infiximab, 2 — etanercept, 5 — rituximab, 1 — abatacept) are demonstrated in this article. Adalimumab was administered hypodermically at the dosage of 40 mg per 2 weeks. The efficacy was assessed according to the criteria of ACR (pediatric). In 4 weeks of treatment in 100% of patients the 30% improvement was established, in 80% of patients — 50% improvement, and in 60% of patients — 70% improvement. In 25 weeks of treatment 30% improvement was documented in 100% of patients (56), 50% improvement — in 91% (51), 70% improvement — in 74% (41). Inactive stage of the disease was established in 24 weeks in 55% of children; in 1 year — in 85%; remission was established in 55% of children. No severe side effects were found. Therefore, the received data show that adalimumab is effective in patients with JIA, both with primary and secondary resistance to other biological agents.https://vsp.spr-journal.ru/jour/article/view/458детиювенильный идиопатический артритадалимумаблечениеблокаторы фактора некроза опухоли αрезистентностьгенно-инженерные препараты |
| spellingShingle | E. I. Alexeeva T. M. Bzarova S. I. Valieva R. V. Denisova K. B. Isaeva A. M. Chomakhidze E. G. Chistyakova T. V. Sleptsova E. V. Mitenko N. I. Taibulatov EFFICACY AND SAFETY OF ANTI-TNFα HUMAN MONOCLONAL ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND SECONDARY RESISTANCE TO OTHER GENETICALLY ENGINEERED BIOLOGICAL AGENTS Вопросы современной педиатрии дети ювенильный идиопатический артрит адалимумаб лечение блокаторы фактора некроза опухоли α резистентность генно-инженерные препараты |
| title | EFFICACY AND SAFETY OF ANTI-TNFα HUMAN MONOCLONAL ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND SECONDARY RESISTANCE TO OTHER GENETICALLY ENGINEERED BIOLOGICAL AGENTS |
| title_full | EFFICACY AND SAFETY OF ANTI-TNFα HUMAN MONOCLONAL ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND SECONDARY RESISTANCE TO OTHER GENETICALLY ENGINEERED BIOLOGICAL AGENTS |
| title_fullStr | EFFICACY AND SAFETY OF ANTI-TNFα HUMAN MONOCLONAL ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND SECONDARY RESISTANCE TO OTHER GENETICALLY ENGINEERED BIOLOGICAL AGENTS |
| title_full_unstemmed | EFFICACY AND SAFETY OF ANTI-TNFα HUMAN MONOCLONAL ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND SECONDARY RESISTANCE TO OTHER GENETICALLY ENGINEERED BIOLOGICAL AGENTS |
| title_short | EFFICACY AND SAFETY OF ANTI-TNFα HUMAN MONOCLONAL ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND SECONDARY RESISTANCE TO OTHER GENETICALLY ENGINEERED BIOLOGICAL AGENTS |
| title_sort | efficacy and safety of anti tnfα human monoclonal antibodies in children with juvenile idiopathic arthritis and secondary resistance to other genetically engineered biological agents |
| topic | дети ювенильный идиопатический артрит адалимумаб лечение блокаторы фактора некроза опухоли α резистентность генно-инженерные препараты |
| url | https://vsp.spr-journal.ru/jour/article/view/458 |
| work_keys_str_mv | AT eialexeeva efficacyandsafetyofantitnfahumanmonoclonalantibodiesinchildrenwithjuvenileidiopathicarthritisandsecondaryresistancetoothergeneticallyengineeredbiologicalagents AT tmbzarova efficacyandsafetyofantitnfahumanmonoclonalantibodiesinchildrenwithjuvenileidiopathicarthritisandsecondaryresistancetoothergeneticallyengineeredbiologicalagents AT sivalieva efficacyandsafetyofantitnfahumanmonoclonalantibodiesinchildrenwithjuvenileidiopathicarthritisandsecondaryresistancetoothergeneticallyengineeredbiologicalagents AT rvdenisova efficacyandsafetyofantitnfahumanmonoclonalantibodiesinchildrenwithjuvenileidiopathicarthritisandsecondaryresistancetoothergeneticallyengineeredbiologicalagents AT kbisaeva efficacyandsafetyofantitnfahumanmonoclonalantibodiesinchildrenwithjuvenileidiopathicarthritisandsecondaryresistancetoothergeneticallyengineeredbiologicalagents AT amchomakhidze efficacyandsafetyofantitnfahumanmonoclonalantibodiesinchildrenwithjuvenileidiopathicarthritisandsecondaryresistancetoothergeneticallyengineeredbiologicalagents AT egchistyakova efficacyandsafetyofantitnfahumanmonoclonalantibodiesinchildrenwithjuvenileidiopathicarthritisandsecondaryresistancetoothergeneticallyengineeredbiologicalagents AT tvsleptsova efficacyandsafetyofantitnfahumanmonoclonalantibodiesinchildrenwithjuvenileidiopathicarthritisandsecondaryresistancetoothergeneticallyengineeredbiologicalagents AT evmitenko efficacyandsafetyofantitnfahumanmonoclonalantibodiesinchildrenwithjuvenileidiopathicarthritisandsecondaryresistancetoothergeneticallyengineeredbiologicalagents AT nitaibulatov efficacyandsafetyofantitnfahumanmonoclonalantibodiesinchildrenwithjuvenileidiopathicarthritisandsecondaryresistancetoothergeneticallyengineeredbiologicalagents |